GLP-1 & compounded medication availability in Wisconsin (2026)

Wisconsin is writing its compounding rulebook’s plain-English companion in real time: demand for compounded tirzepatide and semaglutide prompted the state’s pharmacy regulator to draft a dedicated FAQ, circulated with its August 2026 meeting materials. The draft doesn’t change the rules. It restates them clearly, and this page cites it alongside the underlying law so a Wisconsin reader can see both.

Baseline state

Availability facts last reviewed: November 16, 2026

Ten lines, one Wisconsin answer each

Availability of all ten OrderlyMeds product lines in Wisconsin, with typical delivery times and notes
Product lineAvailable in Wisconsin?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days The product category that prompted Wisconsin’s draft compounding FAQ, shipped here against individual prescriptions.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days Identical national pricing at every dose step.
NAD+ Yes 8–10 business days Via partner pharmacies holding the Wisconsin license the state requires of out-of-state shippers.
Sermorelin Yes 8–10 business days Ordered and priced like every other line here.
Glutathione No N/A Not in the OrderlyMeds catalog right now.
BPC-157 Yes 8–10 business days Peptide injectable. Its federal file is printed below.
TB-500 Yes 8–10 business days Peptide injectable; see the cited section underneath.
KPV No N/A Never carried: peptides in this catalog are injectables, KPV isn’t.
Epitalon Yes 8–10 business days Peptide injectable with its federal entry set out below.
MOTS-c Yes 8–10 business days Peptide injectable; federally its file reads differently than the rest.

When a line doesn’t ship, the table says so in plain sight. Wisconsin figures reviewed November 16, 2026.

Research peptides in Wisconsin: BPC-157, TB-500, KPV, Epitalon & MOTS-c

OrderlyMeds brings four of these five peptides to Wisconsin: BPC-157, TB-500, Epitalon and MOTS-c, compounded as injectables and dispensed only against a prescription bearing your name. KPV stays off the truck in every state, a formulary decision: our peptides are injectables and KPV is not compounded as one. The five federal records below are deliberately individual. One of them (MOTS-c) reads quite differently from its siblings, and pretending otherwise would be the kind of shortcut this page refuses.

BPC-157 in Wisconsin

Compounded for Wisconsin patients as an injectable, one prescription per person. Federal file:

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Wisconsin

On the Wisconsin menu as an injectable compound, individually prescribed. The federal facts:

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Wisconsin

Not dispensed in Wisconsin or elsewhere, because KPV sits outside the injectable-only peptide catalog.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Wisconsin

An injectable compound available to Wisconsin addresses on an individual prescription. Its federal file:

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Wisconsin

Ships to Wisconsin as an injectable compound, individually prescribed, and its federal file is its own rather than the other four’s reworded:

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

Wisconsin’s rulebook, and the FAQ the regulator wrote because of GLP-1s

Wisconsin’s framework rests on two pillars a telehealth patient should know: a licensing wall at the state line, since no out-of-state pharmacy may deliver prescription medication into Wisconsin without a Wisconsin license, and a compounding chapter that imports the national USP standards wholesale. What is new in 2026 is the explanation layer: a compounding FAQ drafted by the regulator itself, prompted, in its own words, by demand for compounded tirzepatide and semaglutide.

No pharmacy located in another state may ship, mail, or otherwise deliver a prescribed drug or device to persons in Wisconsin unless the pharmacy is licensed by the state. Wis. Stat. § 450.065. Source: Wisconsin Statutes § 450.065.

Wisconsin’s compounding chapter, Wis. Admin. Code ch. Phar 15, incorporates the current USP-NF compounding standards by reference, and noncompliance with it is unprofessional conduct that may draw disciplinary action. Source: Wis. Admin. Code ch. Phar 15.

A draft compounding FAQ prepared by the Wisconsin Pharmacy Examining Board — written, per its stated purpose, “in response to the increasing demand for commercially available compounded medications, such as tirzepatide and semaglutide,” and circulated for legal review with the board’s August 2026 meeting materials — restates that compounded essentially-copies of commercially available drugs require a documented, specific, individualized clinical difference (price, patient preference, or convenience do not qualify); that APIs must meet USP-monograph, approved-drug-component, or 503A bulks-list criteria; and that the § 450.065 licensing requirement applies to compounded preparations shipped from out of state. Source: WI Pharmacy Examining Board, draft Pharmaceutical Compounding FAQs (Aug. 2026 meeting materials).

Wisconsin permits prescribing on the basis of a telehealth evaluation that meets the state’s standard of care; no in-person-first rule applies to the medications on this page. Source: Center for Connected Health Policy (CCHP) Policy Finder.

The FAQ is a draft, carrying a placeholder issue date and still with the regulator’s counsel when circulated, so this page treats it as a window into the regulator’s thinking rather than finished rulemaking, and will be updated when a final version issues. None of its content changes anything for an OrderlyMeds order from Milwaukee or Eau Claire: Wisconsin-licensed pharmacies, individual prescriptions, national pricing.

Wisconsin availability FAQs

Can Wisconsin residents order compounded semaglutide?

Yes, filled by partner pharmacies holding the Wisconsin license that state law demands of any out-of-state shipper, from $74/month for the first two months for new customers.

What is the Wisconsin compounding FAQ this page mentions?

A plain-English guidance draft the state’s pharmacy regulator wrote in response to compounded GLP-1 demand, circulated with its August 2026 meeting materials. It restates existing law; the section above quotes and links it.

Do research peptides ship to Wisconsin?

Four do: BPC-157, TB-500, Epitalon and MOTS-c, as compounded injectables on individual prescriptions. KPV isn’t compounded as an injectable and so isn’t carried. Each one’s federal record appears above.

How long does shipping to Wisconsin take?

The OrderlyMeds published window is 8–10 business days from signup; Wisconsin orders keep to it.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone